Cargando…

The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy

Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infa...

Descripción completa

Detalles Bibliográficos
Autores principales: Simek, Stanislav, Motovska, Zuzana, Hlinomaz, Ota, Kala, Petr, Hromadka, Milan, Knot, Jiri, Varvarovsky, Ivo, Dusek, Jaroslav, Rokyta, Richard, Tousek, Frantisek, Svoboda, Michal, Vodzinska, Alexandra, Mrozek, Jan, Jarkovsky, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464834/
https://www.ncbi.nlm.nih.gov/pubmed/32781780
http://dx.doi.org/10.3390/jcm9082555
_version_ 1783577454706688000
author Simek, Stanislav
Motovska, Zuzana
Hlinomaz, Ota
Kala, Petr
Hromadka, Milan
Knot, Jiri
Varvarovsky, Ivo
Dusek, Jaroslav
Rokyta, Richard
Tousek, Frantisek
Svoboda, Michal
Vodzinska, Alexandra
Mrozek, Jan
Jarkovsky, Jiri
author_facet Simek, Stanislav
Motovska, Zuzana
Hlinomaz, Ota
Kala, Petr
Hromadka, Milan
Knot, Jiri
Varvarovsky, Ivo
Dusek, Jaroslav
Rokyta, Richard
Tousek, Frantisek
Svoboda, Michal
Vodzinska, Alexandra
Mrozek, Jan
Jarkovsky, Jiri
author_sort Simek, Stanislav
collection PubMed
description Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infarction (STEMI) patients enrolled in the PRAGUE-18 (prasugrel vs. ticagrelor in pPCI) study were analyzed. Ischemic and bleeding event rates were calculated for patients with and without diabetes. The independent impact of diabetes on outcomes was evaluated after adjustment for outcome predictors. Results: The prevalence of DM was 20% (N = 250). Diabetics were older and more often female. They were more likely to have hypertension, hyperlipoproteinemia, multivessel coronary disease and left main disease, and be obese. The primary net-clinical endpoint (EP) containing death, spontaneous nonfatal MI, stroke, severe bleeding, and revascularization at day 7 occurred in 6.1% of patients with, and in 3.5% of patients without DM (HR 1.8; 95% CI 0.978–3.315; p = 0.055). At one year, the key secondary endpoint defined as cardiovascular death, spontaneous MI, or stroke occurred in 8.8% with, and 5.5% without DM (HR 1.621; 95% CI 0.987–2.661; p = 0.054). In those with DM the risk of total one-year mortality (6.8% vs. 3.9% (HR 1.773; 95% CI 1.001–3.141; p = 0.047)) and the risk of nonfatal reinfarction (4.8% vs. 2.2% (HR 2.177; 95% CI 1.077–4.398; p = 0.026)) were significantly higher compared to in those without DM. There was no risk of major bleeding associated with DM (HR 0.861; 95% CI 0.554–1.339; p = 0.506). In the multivariate analysis, diabetes was independently associated with the one-year risk of reinfarction (HR 2.176; 95% Confidence Interval, 1.055–4.489; p = 0.035). Conclusion: Despite best practices STEMI treatment, diabetes is still associated with significantly worse prognoses, which highlights the importance of further improvements in the management of this high-risk population.
format Online
Article
Text
id pubmed-7464834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74648342020-09-04 The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy Simek, Stanislav Motovska, Zuzana Hlinomaz, Ota Kala, Petr Hromadka, Milan Knot, Jiri Varvarovsky, Ivo Dusek, Jaroslav Rokyta, Richard Tousek, Frantisek Svoboda, Michal Vodzinska, Alexandra Mrozek, Jan Jarkovsky, Jiri J Clin Med Article Purpose: To investigate the prognostic significance of diabetes mellitus (DM) in patients with high risk acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (pPCI) in the era of potent antithrombotics. Methods: Data from 1230 ST-segment elevation myocardial infarction (STEMI) patients enrolled in the PRAGUE-18 (prasugrel vs. ticagrelor in pPCI) study were analyzed. Ischemic and bleeding event rates were calculated for patients with and without diabetes. The independent impact of diabetes on outcomes was evaluated after adjustment for outcome predictors. Results: The prevalence of DM was 20% (N = 250). Diabetics were older and more often female. They were more likely to have hypertension, hyperlipoproteinemia, multivessel coronary disease and left main disease, and be obese. The primary net-clinical endpoint (EP) containing death, spontaneous nonfatal MI, stroke, severe bleeding, and revascularization at day 7 occurred in 6.1% of patients with, and in 3.5% of patients without DM (HR 1.8; 95% CI 0.978–3.315; p = 0.055). At one year, the key secondary endpoint defined as cardiovascular death, spontaneous MI, or stroke occurred in 8.8% with, and 5.5% without DM (HR 1.621; 95% CI 0.987–2.661; p = 0.054). In those with DM the risk of total one-year mortality (6.8% vs. 3.9% (HR 1.773; 95% CI 1.001–3.141; p = 0.047)) and the risk of nonfatal reinfarction (4.8% vs. 2.2% (HR 2.177; 95% CI 1.077–4.398; p = 0.026)) were significantly higher compared to in those without DM. There was no risk of major bleeding associated with DM (HR 0.861; 95% CI 0.554–1.339; p = 0.506). In the multivariate analysis, diabetes was independently associated with the one-year risk of reinfarction (HR 2.176; 95% Confidence Interval, 1.055–4.489; p = 0.035). Conclusion: Despite best practices STEMI treatment, diabetes is still associated with significantly worse prognoses, which highlights the importance of further improvements in the management of this high-risk population. MDPI 2020-08-06 /pmc/articles/PMC7464834/ /pubmed/32781780 http://dx.doi.org/10.3390/jcm9082555 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Simek, Stanislav
Motovska, Zuzana
Hlinomaz, Ota
Kala, Petr
Hromadka, Milan
Knot, Jiri
Varvarovsky, Ivo
Dusek, Jaroslav
Rokyta, Richard
Tousek, Frantisek
Svoboda, Michal
Vodzinska, Alexandra
Mrozek, Jan
Jarkovsky, Jiri
The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title_full The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title_fullStr The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title_full_unstemmed The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title_short The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
title_sort effect of diabetes on prognosis following myocardial infarction treated with primary angioplasty and potent antiplatelet therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464834/
https://www.ncbi.nlm.nih.gov/pubmed/32781780
http://dx.doi.org/10.3390/jcm9082555
work_keys_str_mv AT simekstanislav theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT motovskazuzana theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT hlinomazota theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT kalapetr theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT hromadkamilan theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT knotjiri theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT varvarovskyivo theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT dusekjaroslav theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT rokytarichard theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT tousekfrantisek theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT svobodamichal theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT vodzinskaalexandra theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT mrozekjan theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT jarkovskyjiri theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT theeffectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT simekstanislav effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT motovskazuzana effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT hlinomazota effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT kalapetr effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT hromadkamilan effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT knotjiri effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT varvarovskyivo effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT dusekjaroslav effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT rokytarichard effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT tousekfrantisek effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT svobodamichal effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT vodzinskaalexandra effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT mrozekjan effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT jarkovskyjiri effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy
AT effectofdiabetesonprognosisfollowingmyocardialinfarctiontreatedwithprimaryangioplastyandpotentantiplatelettherapy